Experimental Bone Marrow Transplant Protocol

Inclusion Criteria

• •Recipient
• •Ages 10-55 years inclusive (but less than 56)
• •Chronic myelogenous leukemia in chronic phase
• •A) Patients not treated with STI 571 under the age of 41 (subject to regular DSMB review).
• •B) 10-55 age limits patients in chronic phase who have failed treatment with STI-571.
• •C) 10-55 age limits patients in accelerated phase or blast transformation.
• •Acute lymphoblastic leukemia, any of these categories: Adults (greater than 18 years) in first remission with high-risk features (presenting leukocyte count greater than 100,000/cu mm, Karyotypes t9; 22, t4, t19, t11, biphenotypic leukemia) All second or subsequent remissions, primary induction failure, partially responding or untreated relapse.
• •Acute myelogenous leukemia (AML): AML in first remission Except AML with good risk karyotypes: AML M3 (t15; 17), AML M4Eo (inv 16), AML t (8; 21). All AML in second or subsequent remission, primary induction failure and resistant relapse.
• •Myelodysplastic syndromes, any of these categories: refractory anemia with transfusion dependence, refractory anemia with excess of blasts, transformation to acute leukemia, chronic myelomonocytic leukemia.
• •Myeloproliferative disorders (myelofibrosis, polycythemia vera, essential thrombocythemia) in transformation to acute leukemia
• •Chronic lymphocytic leukemia refractory to fludarabine treatment and with bulky progressive disease or with thrombocytopenia (less than or equal to 100,000/ml) or anemia (less than or equal to 10g/dl) not due to recent chemotherapy.
• •Non-Hodgkin s lymphoma including Mantle cell lymphoma relapsing or refractory to current chemotherapy and monoclonal antibody treatment and unsuitable for autologous stem cell transplantation.
• •No major organ dysfunction precluding transplantation.
• •DLCO greater than or equal to 60% predicted.
• •Left ventricular ejection fraction: greater than or equal to 40% predicted.
• •ECOG performance status of 0 or 1.
• •For adults: Ability to comprehend the investigational nature of the study and provide informed consent. For minors: Written informed consent from one parent or guardian. Informed oral consent from minors: The process will be explained to the minor on a level of complexity appropriate for their age and ability to comprehend.
• •Negative pregnancy test for women of childbearing age.
• •HLA 6/6 identical family donor
• •Weight greater than or equal to 18 kg
• •Age greater than or equal to 2 or less than or equal to 80 years old
• •Fit to receive G-CSF and give peripheral blood stem cells (normal blood count, normotensive, no history of stroke)
• •For adults: Ability to comprehend the investigational nature of the study and provide informed consent. For minors: Written informed consent from one parent or guardian and informed assent: The process will be explained to the minor on a level of complexity appropriate for their age and ability to comprehend.